Status Epilepticus Clinical Trial
Official title:
Use of Lorazepam for the Treatment of Status Epilepticus
The purpose of this study is to gather the data to: 1) determine the best dose, and 2) evaluate its effectiveness and safety in stopping seizures. Part 1 is a pharmacokinetic study (study of how much drug is found in the body after it is given through a vein and how fast the body gets rid of the drug).
Lorazepam is in a class of drugs called benzodiazepines that is used to treat seizures. Lorazepam has been widely used to treat children who have repeated or long seizures, a condition known as status epilepticus (SE). However, lorazepam is not currently approved by the FDA for use in children under 18 years of age. Therefore, the purpose of this study is to gather the data needed for FDA approval. Specifically, we will 1) determine the best dose, and 2) evaluate its effectiveness and safety in stopping seizures. Part 1 is a pharmacokinetic study. These are studies designed to identify and describe one or more of the following basic pharmacological concepts in humans: absorption (i.e. how much gets into the body); distribution (i.e. where it goes in the body); and metabolism and elimination (i.e. how the body gets rid of the medication and how long it takes). The study procedures involve taking blood samples from children, taking their vital signs, and conducting physical examinations. Informed consent will be obtained from all participants as required by federal guidelines. Patients will be divided into two groups. The first group will be patients who present to one of the 10 participating Emergency Rooms (ERs) in status epilepticus (repeated or continuous seizures). We will either ask for consent in the ER, or if we know they have a seizure disorder and have frequent visits to the ER, consent them beforehand for future visits to the ER. The second group will include patients who have a known seizure disorder and agree to be electively admitted to the hospital for a dose of lorazepam when they are not having seizures. We will draw blood samples from patients for up to 48 hours and then follow up via telephone for 30 days from the day the medication was given to assess for side effects. ;
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03883516 -
Improving Emergency Management of Status Epilepticus
|
N/A | |
Recruiting |
NCT03378687 -
A Clinical Study of Children With Status Epilepticus in China
|
N/A | |
Recruiting |
NCT00362141 -
Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus
|
Phase 2 | |
Recruiting |
NCT05140265 -
De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information
|
||
Active, not recruiting |
NCT04391569 -
Randomized Therapy In Status Epilepticus
|
Phase 3 | |
Recruiting |
NCT06017973 -
The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus
|
N/A | |
Completed |
NCT06334796 -
Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology
|
Early Phase 1 | |
Recruiting |
NCT05491590 -
Patient-reported Outcome After Status Epilepticus
|
||
Recruiting |
NCT04421846 -
Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis
|
N/A | |
Completed |
NCT02958605 -
Smartphone Apps for Pediatric Resuscitation
|
N/A | |
Completed |
NCT02239380 -
Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan
|
Phase 3 | |
Completed |
NCT01796574 -
Ketogenic Diet for Refractory Status Epilepticus
|
N/A | |
Completed |
NCT02381977 -
Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment
|
N/A | |
Completed |
NCT00004297 -
Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus
|
Phase 3 | |
Completed |
NCT03905798 -
LORA-PITA IV General Investigation
|
||
Recruiting |
NCT05591508 -
Ketogenic Diet for Status Epilepticus in Children Post Cessation of Convulsive Status Epilepticus
|
N/A | |
Completed |
NCT00735527 -
Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children
|
Phase 3 | |
Terminated |
NCT00265616 -
Treatment of Refractory Status Epilepticus
|
Phase 3 | |
Enrolling by invitation |
NCT06403150 -
The Efficacy and Safety of Levetiracetam Versus Fosphenytoin in Convulsive Status Epilepticus
|
Phase 4 | |
Recruiting |
NCT05246566 -
Assessment of Adults Epidemiological Characteristics of Status Epilepticus in the French West Indies and in French Guiana
|